Changes And Relations Of Soluble Plasma Myeloperoxidase And High Density Lipoprotein-cholesterol Levels In Patients With Coronary Heart Disease

Objective: Our study, by measuring the MPO and lipoprotein of plasma in different coronary heart disease patients, is aiming to observe the effects on the relationship of MPO and coronary heart disease in states of high and low HDL-cholesterol (HDL-C) levels; to explore the relationship between plasma MPO and ACS and the factors that affect them; to search combined-biomarker that can predict ACS.Methods: Eighty six patients were included in our study. They were divided into three groups: acute coronary syndrome (ACS) group (n=36), stable angina pectoris (SAP) group (n=30) and the control group(n=20). Plasma MPO was measured by enzyme-linkeimmunosorbent assay (ELISA) according to the manufacturer's instructionsand. Plasma HDL-C measured by chemistry shielding assay. The study is to find if there are any differences between MPO and HDL-C in each group,and to find if there is dependability between them,besides to analyse the relation among MPO and other blood fat and traditional factors. All statistic analysis was performed by SPSS 13.0 version. Results: (1)plasma MPO level in ACS group (354.2±64.6ng/ml) was significantly higher than that in both SAP group (305.4±43.1ng/ml, p＜0.01) and the control group(298.7±51.9ng/ml, P＜0.01). plasma MPO level in patients of SAP group and the control group were not significantly different (P=0.73). Furthermore, Linear correlation analysis show MPO and HDL-C were negatively correlated (r=-0.87, p＜0.01). An inverse correlation between MPO levels and ApoA1 (r=-0.56, P＜0.01) was also found. MPO showed no significant correlation with LDL-C ( r=-0.15, p=0.52). HDL-C level seems affect the relationship between MPO and ACS. When subjects were stratified by HDL-C levels, no significant difference in MPO was found between control (p＞0.05) and ACS patients (p＞0.05) within high HDL-C group (HDL≥1mmol/L), while difference in MPO was statistically significant between control (p＜0.01) and ACS patients (p＜0.01) within group of low HDL-C (HDL-C＜1mmol/L). The correlation of MPO and HDL-C was also HDL-C dependent, namely the correlation between MPO and HDL-C was stronger in low HDL-C group (r=-0.76, p＜0.01) than in high HDL-C group (r=-0.57, p＜0.01). MPO was weakly correlated to hs-CRP (r=0.2,p=0.012). MPO is independence of those traditional factors (sex, age, smoking, history, diabetes, hypertension).Conclusions: Plasma MPO levels are significantly higher in patients with acute coronary syndrome when compared with SAP patients and controls. The relationship between MPO and ACS are HDL-C level dependent, suggesting that MPO and HDL-C may be a clinically significant combined-biomarker for ACS.